As of 2026-10-17, the Intrinsic Value of Isracann Biosciences Inc (IPOT.CN) is -0.13 CAD. This IPOT.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.02 CAD, the upside of Isracann Biosciences Inc is -963.67%.
Based on its market price of 0.02 CAD and our intrinsic valuation, Isracann Biosciences Inc (IPOT.CN) is overvalued by 963.67%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.13 - -0.13 | -0.13 | -963.67% |
| P/E | (0.01) - (0.04) | (0.02) | -264.1% |
| DDM - Stable | (0.25) - (5.24) | (2.75) | -18410.6% |
| DDM - Multi | (0.24) - (4.08) | (0.47) | -3204.7% |
| Market Cap (mil) | 2.63 |
| Beta | 0.04 |
| Outstanding shares (mil) | 175.23 |
| Enterprise Value (mil) | 2.43 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.78% |
| Cost of Debt | 5.00% |
| WACC | 5.73% |